CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Men diagnosed with the least dangerous, localized prostate cancer have only a minimal risk of dying from the disease over the following 20 years, one of the largest and longest studies on the issue found on Tuesday. "These results do not support aggressive treatment of localized, low-grade prostate cancer" by surgery or radiation, the report from the University of Connecticut Health Center said. "Surveillance is really the best option for those patients," added physician Peter Albertsen, who led the study. Albertsen's research, which began with 767 men and covered more than 20 years, also found that the death rate from prostate cancer across the board appears to remain stable beyond 15 years after diagnosis. That contradicts a recent Swedish study that reported a three-fold increase in prostate cancer mortality rates for men who survive more than 15 years after the disease is found. Albertsen, whose findings appeared in this week's Journal of the American Medical Association, said the conflict might be due to differences in how the disease was classified in each patient and how the causes of death were determined. The men in the Connecticut study were between the ages of 55 and 74 when diagnosed with low stages of prostate cancer as far back as 1971, meaning that the tumor had not progressed outside the gland. But they had many grades of tumors, from the least dangerous to the most virulent. The men with low-grade or least dangerous tumors at diagnosis had a low risk of disease progression even after more than 20 years, with 7% dying of prostate cancer. Most died from other identifiable or unknown causes, and 12% were still alive 20 to 33 years after diagnosis. He said both his and the Swedish study do agree that men with tumors rated at the lower end of the Gleason rating system, widely used in the United States to define prostate tumors, rarely die from their disease; but men with tumors rated at the higher end of that scale die from it within five to 10 years of diagnosis, often despite aggressive interventions. How to advise men with tumors in the middle of the scale who otherwise have a life expectancy of greater than 15 years "poses the greatest challenge," he said. (Reuters)
From our Sponsors
Most Popular
31 Period Films of Lesbians and Bi Women in Love That Will Take You Back
December 09 2024 1:00 PM
18 of the most batsh*t things N.C. Republican governor candidate Mark Robinson has said
October 30 2024 11:06 AM
True
After 20 years, and after tonight, Obama will no longer be the Democrats' top star
August 20 2024 12:28 PM
Trump ally Laura Loomer goes after Lindsey Graham: ‘We all know you’re gay’
September 13 2024 2:28 PM
Melania Trump cashed six-figure check to speak to gay Republicans at Mar-a-Lago
August 16 2024 5:57 PM
These 13 major companies caved to the far right and stopped DEI programs
January 24 2025 1:11 PM
True
Latest Stories
It's time to build a sustainable future for LGBTQ+ advocacy work. Here's why
February 06 2025 7:00 AM
Democratic congressmen: Federal personnel office can't discriminate against trans Americans
February 05 2025 8:19 PM
Trump moves to ban international transgender athletes from 2028 Olympic Games
February 05 2025 5:21 PM
Donald Trump bans transgender athletes from playing sports
February 05 2025 4:15 PM
West Point military academy eliminates cadet clubs amid Trump’s diversity crackdown
February 05 2025 2:42 PM
15 Democratic state AGs stand by gender-affirming care
February 05 2025 2:39 PM
American satisfaction with state of LGBTQ+ rights reaches lowest point in over a decade
February 05 2025 2:05 PM
LGBTQ+ non-U.S. citizens at risk under Trump’s immigration crackdown: study
February 05 2025 12:56 PM
Lesbian cop wins $750k in sexual harassment lawsuit against former chief
February 05 2025 11:53 AM